Antibe Therapeutics (ATBPD) Short Interest Ratio & Short Volume

Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 15th, investors have sold 24,800 shares of ATBPD short. Learn More on Antibe Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATBPD shares currently have a short interest ratio of 1.0. Learn More on Antibe Therapeutics's short interest ratio.

Antibe Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 24,800 shares, a decline of 19.2% from the previous total of 30,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Antibe Therapeutics: Prestige Consumer Healthcare Inc. (3.39%), Cytokinetics, Incorporated (12.02%), Rhythm Pharmaceuticals, Inc. (8.81%), Perrigo Company plc (3.59%), Sarepta Therapeutics, Inc. (7.51%), Avidity Biosciences, Inc. (13.47%), Akero Therapeutics, Inc. (9.82%), Ultragenyx Pharmaceutical Inc. (6.28%), PTC Therapeutics, Inc. (7.52%), Zai Lab Limited (8.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($6.62 billion), Analog Devices, Inc. ($4.85 billion), Aon plc ($4.66 billion), DuPont de Nemours, Inc. ($3.84 billion), International Flavors & Fragrances Inc. ($3.60 billion), Moderna, Inc. ($3.22 billion), Snap Inc. ($3.21 billion), Snowflake Inc. ($2.82 billion), The Kroger Co. ($2.52 billion), and The Clorox Company ($2.49 billion). View all of the most shorted stocks.

Short selling ATBPD is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPD, twice per month. The most recent reporting period available is January, 15 2021.